智能真空辅助活检识别新辅助治疗后乳腺病理完全缓解患者
该研究基于457例1-3期乳腺癌患者数据,开发并测试四种多变量算法,利用患者、肿瘤及真空辅助活检变量识别乳腺病理完全缓解。最佳算法在外部验证中假阴性率0%、特异度65.2%,AUC为0.97,可准确筛选无残留癌患者。
要点
- 多变量算法可准确识别新辅助治疗后无残留癌的乳腺癌患者
- 神经网络在外部验证中假阴性率0%、特异度65.2%、AUC 0.97
- 测试集中四种算法假阴性率均为1.2%,特异度52.2%-67.2%
核心结论
- 多变量算法能准确筛选新辅助系统治疗后无残留癌的乳腺癌患者。
研究设计与样本
- 研究使用457例1-3期乳腺癌女性数据,随机按2:1分为训练集和测试集,来自三项试验,术前接受真空辅助活检。
- 开发并测试四种多变量算法:弹性网惩罚逻辑回归、极限梯度提升树、支持向量机和神经网络。
- 最佳算法在独立的第四项试验中验证,样本量50例。
主要发现
- 测试集(n=152)中四种算法假阴性率均为1.2%(85例中1例遗漏残留癌)。
- 测试集中特异度:弹性网逻辑回归52.2%(67例中35例)、XGBoost树55.2%(37例)、SVM 62.7%(42例)、神经网络67.2%(45例)。
- 外部验证(n=50)神经网络假阴性率0%(27例中0例),特异度65.2%(23例中15例)。
- 神经网络ROC曲线下面积为0.97(95%CI 0.94-1.00)。
临床怎么用
- 该多变量算法可辅助识别新辅助治疗后可能无需手术的乳腺癌患者,减少过度治疗。
- 神经网络算法在外部验证中表现良好,假阴性率低,具有临床转化潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neoadjuvant systemic treatment elicits a pathologic complete response (pCR) in about 35% of women with breast cancer. In such cases, breast surgery may be considered overtreatment. We evaluated multivariate algorithms using patient, tumor, and vacuum-assisted biopsy (VAB) variables to identify patients with breast pCR. METHODS: We developed and tested four multivariate algorithms: a logistic regression with elastic net penalty, an Extreme Gradient Boosting (XGBoost) tree, Support Vector Machines (SVM), and neural network. We used data from 457 women, randomly partitioned into training and test set (2:1), enrolled in three trials with stage 1-3 breast cancer, undergoing VAB before surgery. False-negative rate (FNR) and specificity were the main outcome measures. The best performing algorithm was validated in an independent fourth trial. RESULTS: In the test set (n = 152), the logistic regression with elastic net penalty, XGboost tree, SVM, and neural network revealed an FNR of 1.2% (1 of 85 patients with missed residual cancer). Specificity of the logistic regression with elastic net penalty was 52.2% (35 of 67 women with surgically confirmed breast pCR identified), of the XGBoost tree 55.2% (37 of 67), of SVM 62.7% (42 of 67), and of the neural network 67.2% (45 of 67). External validation (n = 50) of the neural network showed an FNR of 0% (0 of 27) and a specificity of 65.2% (15 of 23). Area under the ROC curve for the neural network was 0.97 (95% CI, 0.94-1.00). CONCLUSION: A multivariate algorithm can accurately select breast cancer patients without residual cancer after neoadjuvant treatment.
引用
- Pfob A, Sidey-Gibbons C, Lee HB, et al. Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy. Eur J Cancer. 2020. PMID: 33307491. doi:10.1016/j.ejca.2020.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。